Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Resveratrol for Prevention of Post-ERCP Pancreatitis
NCT02947932Phase 4Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, single-blind trial of resveratrol in pancreatitis (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Frequency of Post-ERCP Pancreatitis at 30 days. Status: unknown.
02
Drugs
resveratrol
03
Conditions
pancreatitis
Beyond the preview
Go deeper on NCT02947932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947932.